Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print May 9, 2006, 10.1148/radiol.2393040884
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2393040884v1
240/1/90    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schnorr, J.
Right arrow Articles by Taupitz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schnorr, J.
Right arrow Articles by Taupitz, M.
(Radiology 2006;240:90-100.)
© RSNA, 2006

Experimental Studies

Focal Liver Lesions: SPIO-, Gadolinium-, and Ferucarbotran-enhanced Dynamic T1-weighted and Delayed T2-weighted MR Imaging in Rabbits1

Jörg Schnorr, DVM, Susanne Wagner, DVM, Claudia Abramjuk, DVM, Randi Drees, DVM, Tania Schink, MSc, Eyk A. Schellenberger, MD, Herbert Pilgrimm, PhD, Bernd Hamm, MD and Matthias Taupitz, MD

1 From the Departments of Radiology (J.S., S.W., C.A., R.D., E.A.S., B.H., M.T.) and Medical Biometry (T.S.), Charité-Universitätsmedizin Berlin, Schumannstrasse 20/21, 10098 Berlin, Germany; and Ferropharm, Forschungslabor, Teltow, Brandenburg, Germany (J.S., S.W., H.P.). Received May 17, 2004; revision requested August 3; revision received May 9, 2005; accepted June 20; final version accepted September 1. Supported by Investitionsbank des Landes Brandenburg, program Produkt- und Verfahrensinnovation im Land Brandenburg, reference 80100562. Address correspondence to J.S. (e-mail: joerg.schnorr{at}charite.de).

Purpose: To compare a superparamagnetic iron oxide (SPIO), VSOP-C184, with a gadopentetate dimeglumine with regard to signal-enhancing effects on T1-weighted dynamic magnetic resonance (MR) images and with another SPIO contrast medium with regard to signal-reducing effects on delayed T2-weighted MR images.

Materials and Methods: All experiments were approved by the responsible Animal Care Committee. Twenty rabbits (five for each contrast agent and dose) implanted with VX-2 carcinoma were imaged at 1.5 T. VSOP-C184 at 0.015 and 0.025 mmol Fe/kg was compared with gadopentetate dimeglumine at 0.15 mmol Gd/kg and ferucarbotran at 0.015 mmol Fe/kg. The imaging protocol comprised a T1-weighted dynamic gradient-echo (GRE) MR before injection and at 6-second intervals for up to 42 seconds after injection and a T2-weighted turbo spin-echo MR before and 5 minutes after injection. Images were evaluated quantitatively, and contrast media were compared by using nonparametric analysis of variance.

Results: At dynamic T1-weighted GRE MR imaging with 0.015-mmol Fe/kg VSOP-C184, 0.025-mmol Fe/kg VSOP-C184, gadopentetate dimeglumine, and ferucarbotran, the median peak contrast-to-noise ratio (CNR) was 20.7 (25th percentile, 16.3; 75th percentile, 22.6), 24.2 (25th percentile, 19.3; 75th percentile, 28.5), 16.4 (25th percentile, 13.7; 75th percentile, 20.3), and 14.0 (25th percentile, 11.4; 75th percentile, 16.8), respectively. Both doses of VSOP-C184 yielded significantly higher CNR (P < .05) than the other two agents. At T2-weighted turbo spin-echo imaging with 0.015-mmol Fe/kg VSOP-C184, 0.025-mmol Fe/kg VSOP-C184, gadopentetate dimeglumine, and ferucarbotran, the median CNR was 15.0 (25th percentile, 13.4; 75th percentile, 21.3), 15.7 (25th percentile, 14.5; 75th percentile, 19.8), 11.3 (25th percentile, 8.2; 75th percentile, 12.2), and 15.7 (25th percentile, 12.5; 75th percentile, 22.4), respectively. There was no significant difference between VSOP-C184 and ferucarbotran; both had a significantly higher CNR than did gadopentetate dimeglumine.

Conclusion: VSOP-C184 produces higher liver-to-tumor contrast at dynamic T1-weighted imaging than does gadopentetate dimeglumine; at delayed T2-weighted imaging, the contrast is comparable to that achieved with ferucarbotran.

© RSNA, 2006